U.K. To Leverage NHS Data As Part Of Broader Stimulus Package, But Details Still Sketchy
Industry welcomed the initiatives, which included making National Health Service clinical data more widely available and strengthening NICE's role.
You may also be interested in...
Negotiations will start in September 2012 on a value-based pricing approach for new medicines in the U.K., and on a new PPRS scheme for currently marketed drugs, with a new suggestion: oncologics previously rejected by NICE might be reviewed again under the new VBP system.
Individual deals with payers or information providers won’t provide pharma with the breadth of outcomes data they need to secure reimbursement for their drugs. A far broader stakeholder consensus is required.
Accessing IMS Health’s European electronic health records and jointly building a customized data analysis platform will inform AstraZeneca’s R&D priorities and support outcomes claims of newly-launched drugs.